(Q35172297)

6 August 2017

1 reference

title

Dementia associated with Parkinson's disease (English)

1 reference

6 August 2017

0 references

1 reference

Murat Emre

1

1 reference

6 August 2017

language of work or name

1 reference

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

229-237

1 reference

The effect of age of disease onset on neuropsychological performance in Parkinson's disease

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Parkinson's disease: Clinical analysis of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Epidemiology of Parkinson's disease in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A Population-Based Investigation of Parkinson's Disease With and Without Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A longitudinal of Parkinson's disease: clinical and neuropsychological correlates of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Frequency of dementia in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A controlled study of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

The Frequency and Associated Risk Factors for Dementia in Patients With Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

An estimate of the incidence of dementia in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Risk of dementia in Parkinson's disease: a community-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

An estimate of the prevalence of dementia in idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Apolipoprotein E4 in Parkinson Disease and Dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Antecedent clinical features associated with dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Early dopaminergic drug-induced hallucinations in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Motor impairment in PD: relationship to incident dementia and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Neuropsychological characteristics of preclinical dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Combined effect of age and severity on the risk of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Are demented patients with Parkinson's disease accurately reflected in prevalence surveys? A survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Dementia and cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Fluctuations in attention: PD dementia vs DLB with parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Different error pattern of episodic and semantic memory in Alzheimer's disease and Parkinson's disease with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Procedural learning and neostriatal dysfunction in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Visuospatial impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Mental deterioration, visuoperceptive disabilities and constructional apraxia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Alzheimer's disease and Parkinson's disease: Comparison of speech and language alterations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

"Tip-of-the-tongue" phenomenon in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Sentence comprehension and praxis deficits in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Sentence comprehension in Parkinson's disease: The role of attention and memory

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Impairment of motor planning in patients with Parkinson's disease: evidence from ideomotor apraxia testing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Relationship of motor symptoms to intellectual deficits in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

The association of incident dementia with mortality in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Intellectual changes in patients with MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cognitive change following MPTP exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Fluctuations in plasma dopamine level impair memory in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A subcortico-cortical cholinergic system is affected in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Basal forebrain neurons in the dementia of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cholinergic-dependent cognitive deficits in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cholinergic deficiency and frontal dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Magnetic resonance imaging in dementia of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

SPECT findings in Parkinson's disease associated with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

(99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

rCBF SPECT in Parkinson's disease patients with mental dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cerebral glucose metabolism in Parkinson's disease with and without dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Clinico-pathological correlations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

A clinicopathologic study of 100 cases of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Morphological substrates of dementia in parkinsonism. A critical update.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Effects of levodopa in Parkinsonian patients with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Dementia and treatment with L-dopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cholinesterase inhibition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Dementia with Lewy bodies: response of delirium-like features to donepezil.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Donepezil for the treatment of psychosis in dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

Cerebral Blood Flow and Dementia in Parkinson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900351-X

7 January 2021

10.1016/S1474-4422(03)00351-X

Identifiers

DOI

1 reference

6 August 2017

1 reference